Affinity Asset Advisors

Ceptur is developing unique and differentiated genetic medicines for patients with unaddressed diseases. The Company’s wholly owned and proprietary U1 Adaptor technology promotes non-genotoxic and long-lasting silencing of disease-causing genes in difficult to target tissues (i.e., outside of the liver and CNS).

Renovacor is a preclinical‑stage biopharmaceutical company focused on developing transformative gene therapy‑based treatments for cardiovascular disease. Renovacor’s lead program is a recombinant adeno-associated virus (AAV)‑based gene therapy for patients suffering from dilated cardiomyopathy (DCM) due to mutations in the Bcl2‑associated athanogene 3 (BAG3) gene. Dilated cardiomyopathy is a condition affecting over 3 million patients in the US and growing steadily. Many patients develop DCM due to ischemic heart disease. Recently subpopulations have been identified that develop DCM due to mutations in specific genes that have been shown to result in the development of DCM. One of these specific genes is the BAG3 gene. The prevalence of disease‑causing BAG3 haploinsufficiency is estimated at approximately 35,000 individuals in the United States, representing an orphan disease by FDA guidelines. It is estimated a similar number of DCM patients with BAG3 mutations exist in Europe. These patients are typically younger and progress to end-stage heart failure sooner than patients with ischemic heart disease. Currently, DCM patients with a BAG3 mutation are treated with standard of care for heart failure. Despite improvements in pharmacotherapy and care, the five‑year survival of a patient with DCM is only 50%. The development of a BAG3 gene replacement therapy for patients with DCM that carry BAG3 mutations could potentially prevent the progression of disease in this otherwise healthy population of young adults.

Kurome Therapeutics is a preclinical stage company focused on subverting cancer's ability to evade therapy. The company is developing therapies that target cancer cells that have co-opted immune signaling pathways to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms.

Identifeye is creating prediction models that combine multiple retinal imaging modalities with expert annotations to create comprehensive and non-invasive health assessments. Identifeye Health is a part of the 4Catalyzer accelerator, which is dedicated to improving patient care globally. It has offices in Guilford, Connecticut, New York City, and Palo Alto, California.

Ceptur is developing unique and differentiated genetic medicines for patients with unaddressed diseases. The Company’s wholly owned and proprietary U1 Adaptor technology promotes non-genotoxic and long-lasting silencing of disease-causing genes in difficult to target tissues (i.e., outside of the liver and CNS).